ABSTRACT
A sthma is a prevalent chronic disease managed with ongoing adjustments of medications. 1 Authors of asthma treatment guidelines suggest that providers consider stepping down asthma medications when asthma is stable for 3 months. 2, 3 For individuals who have stable asthma on low-dose inhaled corticosteroid (ICS), one recommendation is to decrease the ICS dose by 25-50%. 2 Current guideline recommendations are based on limited data. Other options for individuals stable on low-dose ICS include stopping the ICS altogether with no substitute medication, stopping the ICS and substituting a leukotriene receptor antagonist (LTRA), reducing ICS while adding a LTRA, or using ICS on demand based on symptoms (or other parameters). Substituting LTRA or using LTRA to help reduce the ICS dose may be an attractive option for ease of use (tablet rather than inhaler form) and cost. Previous systematic reviews addressed the risks of asthma exacerbation when individuals stable on lowdose ICS stop 4 or reduce ICS. 5 Appreciation of these risks allows patients and providers to make informed decisions about stepping down asthma medicines. The goal of this systematic review was to identify randomized controlled trials (RCT) that compared the risk of asthma exacerbation on substituting LTRAs for ICS to the risk of continuing ICS in individuals with stable asthma. A second goal of the systematic review is to identify RCTs that compared the risk of asthma exacerbation when adding LTRAs to tapering ICS doses in individuals with stable asthma compared with adding placebo.
METHODS

Data Sources and Searches
This systematic review is consistent with the 27-item PRISMA statement checklist. 6 We searched for RCTs with the study intervention of stopping ICS We included studies that had a run-in period of at least 4 weeks with subjects on a stable dose of ICS to ensure a minimum period of asthma stability while participating in the trial. We recognize that 4 weeks is shorter than the 3 months of stability currently suggested by the most recent guidelines. We included studies with 3 or more months of follow-up after randomization to allow a reasonable time period to monitor for an asthma exacerbation to occur, although we recognize that a longer study period would likely detect additional events and provide even more information for a long-term risk estimate. There were no exclusions based on age or sex.
We performed a systematic review of English and non-English articles by using Ovid MEDLINE, Ovid EMBASE, Ovid CENTRAL, and Web of Science (inception to May 17, 2014) . Search terms included antiasthmatic agents, names for medication classes and for specific medications, and numerous descriptors for reducing medications (e.g., step down, wean, withdraw, reduce). The MEDLINE search strategy was modified to accommodate the controlled vocabulary for EMBASE and CENTRAL; text words were used for the search performed in the Web of Science. In addition, we reviewed the reference sections of eligible studies and searched articles that had been cited by the eligible articles by using the Web of Science. We asked content experts for input about additional relevant studies or for any unpublished data pertinent to our research question. We used text words to search the following clinical trial registries for studies: clinicaltrials.gov, clinicaltrialregister.eu, and anzctr.org.au.
Study Selection
Two reviewers working independently and not blinded to the author(s), institution, or journal of publication determined the eligibility of the abstracts identified by using the search strategy. Full-text articles were obtained unless both reviewers determined that the abstract was ineligible for this study. For articles that could not be obtained in full text through the institution's interlibrary loan process and when disagreement existed between the two reviewers about advancing to the full-text review stage, a third reviewer assessed the abstract for criteria to advance to the full-text review stage. If two of the three reviewers recommended a full-text review, then additional efforts were made to obtain the full-text article. The full-text review was also performed in duplicate; disagreements about inclusion of full-text articles were harmonized by consensus. If consensus was not reached, then arbitration by an additional content expert familiar with the predetermined inclusion and exclusion criteria was arranged.
Risk of Bias Assessment
We assessed the following study characteristics to judge the methodological quality of the included studies: how the randomization sequence was generated, how allocation was concealed, whether there were important imbalances in prognostic factors at baseline, which groups were blinded, and how missing outcome data were reported and analyzed. The risk of bias was assessed by using the Cochrane Collaboration risk of bias tool 7 by two independent reviewers. Disagreements about risk of bias assessments were harmonized by consensus.
Data Synthesis and Analysis
We used a random-effects model to calculate the pooled relative risk ratio of an individual who experienced at least one asthma exacerbation if he or she used LTRA rather than placebo when reducing the ICS dose. We selected a random-effects model due to anticipated heterogeneity in how the outcome of asthma exacerbation was defined. We recorded how asthma exacerbation was defined for each included study. We measured inconsistency by using the I 2 test; higher I 2 scores indicated greater inconsistency. We used Review Manager 5.2 (Cochrane Collaboration) software to conduct the analyses.
RESULTS
Search Results
Our initial search strategy identified 840 articles. By using the additional strategies of reviewing the bibliography of the included studies, reviewing a list of studies that cited the included study, searching clinical trial registries, and contacting experts, we identified an additional 292 unique citations. Of the 1132 total unique citations, 54 met criteria for full-text review. Of the 54 full-text citations considered, four met criteria for inclusion. 8 -11 The PRISMA template 6 for study selection is displayed in Fig. 1 .
Substitution of LTRA for ICS as Step-Down Strategy
The study setting was multiple academic centers in North America. Individuals 6 years old and older participated in a 4 -6-week run-in period on fluticasone diskus inhaler 100 g twice daily (beclomethasone 200 g/d equivalent), followed by randomization to continue the same fluticasone dose (n ϭ 165) or substitute montelukast for 16 weeks (n ϭ 165).
D O N O T C O P Y
Treatment failure was defined as any urgent medical visit for asthma, systemic corticosteroids, open-label use of ICS as determined by the provider, decrease in prebronchodilator forced expiratory volume in first second to more than 20% below baseline, decrease in peak flow rate to more than 35% below baseline on 2 consecutive days, use of Ͼ10 puffs of rescue ␤-agonist for 2 consecutive days, patient refusal to continue, or provider judgment for reasons of safety. The treatment failure rates were 20.2% in the continue ICS group and 30.3% in the LTRA group (hazard ratio 1.6; 95% confidence interval, 1.1-2.6) over the 16-week study period.
Use of LTRA or Placebo During ICS Dose Reduction
We identified three studies that met our inclusion criteria, all studies in adolescents and adults Ͼ15 years old who used montelukast 10 mg as the intervention. 9 -11 The ICS dose was reduced by 50% dose multiple times in two of the studies and not specified in the third study. Starting doses for ICS were specified in two of the studies, both of which were in the medium-high ICS dose range (beclomethasone equivalents 800-1600 g for Tohda et al., 10 400 g for Riccioni et al., 11 and not stated for Lofdahl et al.
9
). Asthma exacerbation definitions varied across the three studies. In Lofdahl et al., 9 failed rescue was defined as patients who were unstable and who failed to regain clinical stability after an increase in the dose of corticosteroids and also included withdrawal if a patient required treatment with systemic corticosteroid. 9 In Tohda et al., 10 the patients were withdrawn from the study if asthma could not be controlled after increasing the dose of ICS. In Riccioni et al., 11 we decided to count an asthma exacerbation if the dose of ICS could not be reduced due to worsening symptoms or if systemic corticosteroids were used. Study characteristics are summarized in Table 1 .
Comparing LTRA versus placebo in patients with stable asthma when reducing ICS found a modestly decreased risk ratio that favored LTRA of 0.57 (95% CI, 0.36 -0.90; I 2 ϭ 0%) (Fig. 2 a) . One of the studies had a fixed ICS dosing schedule; 11 therefore, we compared only the two studies 9, 10 with flexible ICS schedules for final ICS dose and found no significant different in standardized mean ICS dose at study conclusion, -0.03 (95% CI, -0.52 to 0.45; I 2 ϭ 83%) (Fig. 2 b) . 
D O N O T C O P Y
Risk of Bias
The risk of bias was assessed for each of the included studies, and these are summarized in Table 2 . Notably, drop-out rates (not including those with treatment failure) for the trials that added LTRA for tapering ICS were 5% LTRA and 6% placebo for Tohda et al., 10 5% for LTRA and 4% placebo for Riccioni et al., 11 and 9% LTRA and 13% placebo for Lofdahl et al. 9 There were concerns about high risks of bias in one of the included studies 11 ; therefore, the main outcome of asthma exacerbations was performed excluding this study yielding a similar conclusion (relative risk ratio 0.57; 95% CI, 0.36 -0.90; I 2 ϭ 0%).
DISCUSSION
We performed a systematic review of RCTs with the intervention of substituting LTRA for ICS versus continuing the ICS and found only one trial that met our predetermined inclusion and exclusion criteria. Evidence for potential step-down methods for individuals who are currently stable on low-dose ICS is summarized in Table 3 . The clinical implication of our findings is that the clinical trial evidence for estimating the risk of asthma exacerbation when substituting LTRA for ICS is low and is currently based on a single trial.
Although this may be an option that patients and providers continue to consider, we have more confident estimates in the risks for stopping ICS or reducing ICS, with the latter having a lower risk for future asthma exacerbations than the former.
We performed a second systematic review with a meta-analysis to estimate risk of reducing ICS with the addition of LTRA and found a modest risk reduction compared with placebo for the outcome of asthma exacerbation. Subjects in these studies started with a medium-high dose of ICS; therefore, these risk estimates are not directly comparable with the risks listed in Table 3 . A similar analysis was performed by Ducharme 12 in a 2011 systematic review that considered multiple questions about the use of LTRAs for asthma. In their analysis, they included three articles that we did not include due to these articles not meeting our prespecified criteria for having a 4-week run-in period.
13-15 Ducharme 12 identified four studies (two of montelukast and two of zafirlukast) that together showed no difference in ICS dose at study conclusion between the LTRA and placebo groups, similar to our findings. However, a significantly higher number of study withdrawals for poor asthma control was seen in the placebo group compared with the LTRA group as Rx ϭ treatment.
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D O N O T C O P Y
ICS doses were tapered, which indicates a possible modest ICS-sparing effect, similar to the modest effect we found with LTRA as reducing risk of asthma exacerbation. 12 Further supporting an overall role of LTRA in reducing risk of asthma exacerbation was a recently published systematic review and meta-analysis that found a reduced odds of asthma exacerbation of 0.60 (95% CI, 0.49 -0.74) for LTRA compared with placebo. 16 Despite slightly different inclusion-exclusion criteria and an updated search in this systematic review, we came to similar conclusions that adding LTRA allows slightly safer tapering of ICS in individuals Ͼ15 years old.
The main limitation of this systematic review was that only one study was identified that was pertinent to our research question about substitution of LTRA for ICS as a step-down strategy. This limits our ability to compare substitution of LTRA for ICS with other stepdown strategies. Second, we found a small reduction in risk for asthma exacerbation when tapering ICS with LTRAs, which may be helpful when considering how to taper from medium-high dose ICS. This strategy, however, would need to be compared directly with alternative strategies, e.g., the addition of long-acting ␤-agonists. These conclusions must also weigh the potential risk of publication bias, which is difficult to estimate with only three included studies. 9 -11 To summarize the findings from this systematic review, we included a summary table that uses the GRADE format (Table 4) . 17 The findings from this study could potentially further inform the Global Initiative for Asthma guideline recommendations on stepping down. Grade B evidence (a single high-quality RCT) against substituting LTRA for ICS is the only evidence we found in the systematic review for this step-down option. Grade A evidence (meta-analysis) of three studies of medium-high quality for adding LTRA 9 -11 during ICS taper could be considered so to increase the specificity of the current grade B recommendation for reducing ICS while adding other controllers; however, the asthma exacerbation risk reduction we found in this meta-analysis was modest and should only be applied to those Ͼ15 years old. Using a LTRA to substitute for ICS may still be a reasonable option for individuals based on a preference for a tablet over an inhaler, cost, or improved adherence. Decisions on how to best step down asthma medication remains individualized and requires discussion between the provider and the patient. More research, particularly clinical trials with interventions that use different step-down options, is needed so that patients and their providers have a stronger body of evidence to make informed decisions about stepping down asthma medication. 
